For Ph-negative ALL, in August 2017, the Food and Drug Administration (FDA) approved the use of inotuzumab ozogamicin (28, 29), a monoclonal antibody anti-CD22, but also chimeric antigen receptor (CAR) T-cells (30). Here, CD22 is linked to acute lymphoblastic leukemia.